I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US
CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017
CLINUVEL today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company’s 2017 Annual General Meeting
CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).
Appendix 3B - New issue announcement
Appendix 4E - Preliminary Final Report 2016/17